This is the future location of the new national innovation cluster

Mölndal and Goco Health Innovation City will be the site of a new national innovation cluster for advanced therapies. The business community and the Swedish government are splitting the costs of the project, which is expected to produce new treatments for common diseases such as cancer and diabetes.

In March, Vinnova was commissioned by the Swedish government to establish the new cluster, as Life Science Sweden previously reported, and the plans have now taken shape.

The cluster is designed to serve as a national infrastructure and competence hub that will benefit companies throughout the country and strengthen Sweden’s competitiveness in cell and gene therapies and precision medicine.

Through Vinnova, the Swedish government is contributing SEK 80 million during 2023-24, and the business community, via the CCRM Nordic consortium, is contributing the same amount. The consortium includes Astra Zeneca, which operates a large research facility in Mölndal, outside Gothenburg.

“For us at Astra Zeneca, it is particularly exciting that the innovation cluster is located in Goco Health Innovation City, next door to our research facility in Gothenburg. It gives us proximity to vital infrastructure for advanced therapies and opens up entirely new opportunities for collaboration in our work to develop new cell and gene technologies to treat diseases that affect millions of patients around the world,” says Per Alfredsson, CEO of Astra Zeneca, in a comment to Life Science Sweden.

Other companies in the consortium are Combigene, Cytiva Sweden, Cytiva Test Center, Getinge, Goco Development, Takara Bio Europe, Tataa Biocenter and Verigraft.

The aim of the innovation cluster is to connect previous major infrastructure investments, such as the innovation hub at Northx Biologics in Matfors and the Cytiva Test Centre in Uppsala.

Artikeln är en del av vårt tema om News in English.

Kommentera en artikel
Utvalda artiklar


Sänd till en kollega